New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline November 12, 2023 by Leave a Comment Last Updated on November 12, 2023 by [#item_full_content] Share this:TwitterFacebookMorePrintLike this:Like Loading... Related Spread the word
Leave a Reply